Corbus director granted RSUs and options
Corbus Pharmaceuticals Holdings, Inc. director Anne Altmeyer reported equity compensation awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Corbus Pharmaceuticals Holdings, Inc. director Anne Altmeyer reported equity compensation awards. On May 19, 2026, she received 3,800 restricted stock units (RSUs) that will vest 100% one year from the grant date and be settled in common shares. She was also granted stock options on 12,300 shares of common stock at an exercise price of $9.15 per share, which will likewise vest 100% after one year. Following the RSU grant, she directly holds 9,991 shares of common stock, and the disclosure notes this amount includes 8,600 unvested RSUs subject to prior vesting schedules.
Insider Trade Summary
Grant/Award: 16,100 shares
Grant/Award
2 txns
Insider
Altmeyer Anne
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock options (right to buy) | 12,300 | $0.00 | $0.00 |
| Grant/Award | Common Stock, par value $0.0001 per share | 3,800 | $0.00 | $0.00 |
Holdings After Transaction:
Stock options (right to buy) — 12,300 contracts (Direct);
Common Stock, par value $0.0001 per share — 9,991 shares (Direct)
Footnotes (3)
- F1. On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
- F2. This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.
- F3. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.
Key Figures
RSU grant size: 3,800 RSUs
Option grant size: 12,300 options
Option exercise price: $9.15 per share
+2 more
5 metrics
RSU grant size
3,800 RSUs
Granted May 19, 2026; vest 100% after one year
Option grant size
12,300 options
Granted May 19, 2026; underlying common stock
Option exercise price
$9.15 per share
Stock options on Corbus Pharmaceuticals common stock
Shares held after grant
9,991 shares
Common stock directly held following RSU grant
Previously unvested RSUs
8,600 RSUs
Unvested RSUs included in post-transaction holdings
Key Terms
restricted stock units ("RSUs"), vesting schedule, Equity Compensation Plan, stock options (right to buy)
4 terms
restricted stock units ("RSUs") financial
"On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vesting schedule financial
"This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
Equity Compensation Plan financial
"The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan"
A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.
stock options (right to buy) financial
"Stock options (right to buy)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Anne Altmeyer receive from Corbus Pharmaceuticals (CRBP)?
Anne Altmeyer received 3,800 restricted stock units and options on 12,300 shares. The RSUs settle in common stock, while the options allow future purchases at a fixed $9.15 exercise price, subject to vesting after one year.
When do Anne Altmeyer’s new RSUs and options in CRBP vest?
Both the 3,800 RSUs and the 12,300 stock options vest 100% on the one-year anniversary of the May 19, 2026 grant. Before vesting, she does not fully own the RSU shares or have exercisable rights to the options.
What is the exercise price of Anne Altmeyer’s new Corbus Pharmaceuticals stock options?
The newly granted stock options cover 12,300 shares at an exercise price of $9.15 per share. This means she can purchase CRBP common stock at $9.15 once the options fully vest on the one-year anniversary of the grant date.
Under what plan were Anne Altmeyer’s Corbus Pharmaceuticals options granted?
The option award was granted under Corbus Pharmaceuticals’ 2024 Equity Compensation Plan. This plan governs how equity-based awards like stock options are issued to directors, including vesting terms and other conditions tied to the grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
